SEC Form 4 · accession 0001493152-17-002372
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Jonathan Frederick Head
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Mar 10, 2017
Accepted (ET)
Mar 13, 2017 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF1 | Mar 10, 2017 | J | 2,892,000 | — | A | 2,892,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities issued pursuant to the terms and conditions of a Contribution Agreement to the Property of Trust F/2868 entered into among OncBioMune Pharmaceuticals, Inc., Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March 10, 2017 as filed by the Issuer as Exhibit 10.1 to its Current Report on Form 8-K as filed with the SEC on March 13, 2017.